1. Home
  2. LEU vs KROS Comparison

LEU vs KROS Comparison

Compare LEU & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Centrus Energy Corp.

LEU

Centrus Energy Corp.

BUY

Current Price

$264.66

Market Cap

4.2B

Sector

Industrials

ML Signal

BUY

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

HOLD

Current Price

$20.14

Market Cap

655.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEU
KROS
Founded
1998
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Mining & Quarrying of Nonmetallic Minerals (No Fuels)
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
655.9M
IPO Year
1998
2020

Fundamental Metrics

Financial Performance
Metric
LEU
KROS
Price
$264.66
$20.14
Analyst Decision
Buy
Buy
Analyst Count
11
12
Target Price
$235.80
$22.20
AVG Volume (30 Days)
878.5K
1.0M
Earning Date
02-05-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
31.25
N/A
EPS
6.17
1.57
Revenue
$454,100,000.00
$246,718,000.00
Revenue This Year
$1.93
$6,876.34
Revenue Next Year
$7.86
N/A
P/E Ratio
$42.43
$12.87
Revenue Growth
15.25
37798.31
52 Week Low
$49.40
$9.12
52 Week High
$464.25
$22.55

Technical Indicators

Market Signals
Indicator
LEU
KROS
Relative Strength Index (RSI) 50.60 57.46
Support Level $220.50 $20.73
Resistance Level $241.30 $21.75
Average True Range (ATR) 20.26 1.06
MACD 0.80 -0.12
Stochastic Oscillator 66.36 58.36

Price Performance

Historical Comparison
LEU
KROS

About LEU Centrus Energy Corp.

Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: